Table 2

Patient distribution according to clinical grade on hospitalization on the WFNS scale over a series of different endovascular treatments

Viñuela
1994
Brilstra
1999
Byrne
1999
ISAT
2002
Henkes
2004
Holmin
2008
Resat
2010
CLARITY
2010
Murias
2013
WFNS at hospitalization
 I20.3%51.1%63%26%13.7%20%44.2%38.6%
 II26.1%24.6%25%25.3%53.7%30%21.5%13.1%
 III30%13.6%6%21.1%15%20%3.7%6.7%
 I—III76.4%80%89.3%94%72.4%82.4%70%69.4%58.4%
 IV17.1%6.9%4%15.9%14%20%16.3%23.9%
 V6.5%3.8%2%8%3.6%10%14.3%17.5%
 IV—V23.6%20%10.7%6%23.9%17.6%30%30.6%41.6%
Total403509317107310873204786773251
mRS 1 year
 019.1%53%53.1%38%
 129.1%19.1%19.1%15%
 225.7%13%45%10%
 0–284.9%89.2%81.4%73.9%75%85.2%75%76.7%63%
 310.1%8.7%2.9%6%
 43.2%3%2.4%11%
 55.8%0.4%1.8%5%
 67.5%7.0%6%2.7%16.3%15%
 3–615.1%10.8%18.6%26.1%25%14.8%25%23.3%37%
  • It is worth noting that ISAT is a prospective trial that compares endovascular and surgical therapies, CLARITY is the only trial that analyses endovascular treatment as a first choice treatment for non-selected patients, and the Brilstra study is a meta-analysis. The results are shown in terms of the independence and mortality of our series compared with those in related articles, using the modified Rankin Scale (mRS) analysis after 1 month.

  • ISAT, International Subarachnoid Aneurysm Trial; WFNS, World Federation of Neurosurgical Societies.